The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

This interview discusses Little Green Pharma’s (ASX:LGP) record-breaking quarterly results for June 2024, highlighting a 12% increase in revenue and significant cash receipts. CEO Paul Long elaborates on the company’s growth drivers, including new product sales in Australia and Europe, and outlines their strategy to maintain market share and expand in emerging European markets.

lgp by the numbers
More From The Market Online

Eastern Gas Corporation jumps on strong gas shows at Macalister

Eastern Gas Corporation has obtained positive gas hits from drilling of the Venus-2H horizontal appraisal well…

Pro Medicus signs $25M contract with US-based Valley Health

Pro Medicus' US subsidiary Visage Imaging has signed a seven-year, $25 million contract with Valley Health…

Noble Helium expanding portfolio with move to acquire Earth Source Hydrogen

Noble Helium has entered into a binding agreement to acquire 100% of the issued share capital…

Janison Education Group secures landmark UK contract with NFER

Janison Education Group has been named as principal technology subcontractor under a major Scottish government contract.